Minocycline for retinitis pigmentosa
Treatments studied
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether a common antibiotic called minocycline can slow the vision loss caused by retinitis pigmentosa. It is a randomized, double-blind study, meaning neither you nor your doctor will know if you are getting the real drug or a placebo (inactive pill). If it works, it could help preserve your remaining vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have retinitis pigmentosa (a genetic condition that causes gradual vision loss and trouble seeing at night).
- Your eyes must still produce some electrical signal when tested with a special light (ERG test).
- Your vision in both eyes must be good enough to read letters on an eye chart (better than counting fingers).
- You cannot have other major eye diseases like glaucoma, macular degeneration, or diabetic retinopathy.
- You cannot have had any eye surgery, and you must not be allergic to tetracycline antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an extract from a type of algae that is rich in a special form of vitamin A. It may help improve vision for people with retinitis pigmentosa caused by certain gene mutations that affect how the eye processes vitamin A.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This study tests whether a single injection of umbilical cord stem cells around the eye can safely help slow or improve vision loss from retinitis pigmentosa, a genetic eye disease. It also checks how long any benefits might last, using regular eye tests and a quality-of-life survey.
This trial tests whether a powder made from a special algae can help improve vision in teenagers with retinitis pigmentosa, a genetic condition that causes vision loss. The algae contains a form of vitamin A that might protect the retina.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.